PMADS

Id:	acc2181
Group:	2sens
Protein:	PTEN
Gene Symbol:	PTEN
Protein Id:	P60484
Protein Name:	PTEN_HUMAN
PTM:	phosphorylation
Site:	Tyr240
Site Sequence:	PTRREDKFMYFEFPQPLPVCG
Disease Category:	Cancer
Disease:	Glioma
Disease Subtype:
Disease Cellline:	patient-derived?glioma stem cell?lines
Disease Info:
Drug:	Ionising radiation
Drug Info:	-
Relation:	PTEN-Tyr240 UP ＋ Ionising radiation ➜ Glioma Aggravate
Effect:	resist
Effect Info:	Protein phosphorylation leads to radioresistance in tumors.
Note:	Non-conventional drugs
Score:	4.5
Pubmed(PMID):	31025173
Sentence Index:	31025173_3-4
Sentence:	"A recent study published by Ma et al. (Cancer Cell 35:504-518, 2019) reported that the phosphorylation of phosphatase and tensin homolog (PTEN) at tyrosine 240 (pY240-PTEN) promotes the radioresistance of human glioma cells. After treatment with IR, the fibroblast growth factor receptor 2 (FGFR2)-mediated phosphorylation that generated pY240-PTEN could effectively promote the decondensation of chromatin through an interaction with Ki-67, leading to DNA damage repair and radioresistance."

Sequence & Structure:

MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

PTEN-Ser294
Cancer	Intensity
BRCA
COAD	-0.741
HGSC
ccRCC	-0.738
GBM
HNSC	1.65
LUAD	-0.543
LUSC	0.557
non_ccRCC	-1.263
PDAC	0.989
UCEC	0.088

PTEN-Ser364
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC	-0.707

PTEN-Ser370
Cancer	Intensity
BRCA
COAD	-1.229
HGSC
ccRCC	0.576
GBM
HNSC
LUAD	1.014
LUSC
non_ccRCC
PDAC
UCEC	-0.361

PTEN-Ser467
Cancer	Intensity
BRCA	0.471
COAD
HGSC	-1.149
ccRCC
GBM	0.677
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTEN-Thr363
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC	-0.707

PTEN-Thr366
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
Y	240	U	Glioblastoma	Phosphorylation	22891331

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb